Log in

NASDAQ:LIFE - aTyr Pharma Stock Price, Forecast & News

$6.16
-0.90 (-12.75 %)
(As of 01/17/2020 04:00 PM ET)
Today's Range
$6.03
Now: $6.16
$6.53
50-Day Range
$3.96
MA: $4.74
$7.06
52-Week Range
$2.76
Now: $6.16
$10.08
Volume310,900 shs
Average Volume1.09 million shs
Market Capitalization$23.96 million
P/E RatioN/A
Dividend YieldN/A
Beta2.48
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:LIFE
CUSIP53217V10
Phone858-731-8389

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$15.70 per share

Profitability

Net Income$-34,510,000.00

Miscellaneous

Employees42
Market Cap$23.96 million
Next Earnings Date3/23/2020 (Estimated)
OptionableOptionable

Receive LIFE News and Ratings via Email

Sign-up to receive the latest news and ratings for LIFE and its competitors with MarketBeat's FREE daily newsletter.


aTyr Pharma (NASDAQ:LIFE) Frequently Asked Questions

What is aTyr Pharma's stock symbol?

aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."

When did aTyr Pharma's stock split? How did aTyr Pharma's stock split work?

aTyr Pharma's stock reverse split on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 28th 2019. An investor that had 100 shares of aTyr Pharma stock prior to the reverse split would have 7 shares after the split.

How were aTyr Pharma's earnings last quarter?

aTyr Pharma Inc (NASDAQ:LIFE) announced its quarterly earnings data on Thursday, November, 14th. The biotechnology company reported ($1.47) EPS for the quarter, missing the consensus estimate of ($1.43) by $0.04. The biotechnology company had revenue of $0.18 million for the quarter, compared to the consensus estimate of $0.06 million. View aTyr Pharma's Earnings History.

When is aTyr Pharma's next earnings date?

aTyr Pharma is scheduled to release their next quarterly earnings announcement on Monday, March 23rd 2020. View Earnings Estimates for aTyr Pharma.

What price target have analysts set for LIFE?

3 equities research analysts have issued 1-year price targets for aTyr Pharma's stock. Their forecasts range from $4.00 to $8.00. On average, they anticipate aTyr Pharma's share price to reach $6.00 in the next twelve months. This suggests that the stock has a possible downside of 2.6%. View Analyst Price Targets for aTyr Pharma.

What is the consensus analysts' recommendation for aTyr Pharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for aTyr Pharma.

Has aTyr Pharma been receiving favorable news coverage?

Media coverage about LIFE stock has been trending somewhat negative recently, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. aTyr Pharma earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for aTyr Pharma.

Are investors shorting aTyr Pharma?

aTyr Pharma saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 6,700 shares, an increase of 91.4% from the December 15th total of 3,500 shares. Based on an average daily trading volume, of 215,500 shares, the short-interest ratio is currently 0.0 days. Approximately 0.2% of the shares of the company are sold short. View aTyr Pharma's Current Options Chain.

Who are some of aTyr Pharma's key competitors?

What other stocks do shareholders of aTyr Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), Crispr Therapeutics (CRSP), Amicus Therapeutics (FOLD), QUALCOMM (QCOM), Rigel Pharmaceuticals (RIGL), Gilead Sciences (GILD) and Idera Pharmaceuticals (IDRA).

Who are aTyr Pharma's key executives?

aTyr Pharma's management team includes the folowing people:
  • Dr. Sanjay S. Shukla, Pres, CEO & Director (Age 47)
  • Ms. Jill M. Broadfoot, CFO & Principal Accounting Officer (Age 57)
  • Dr. John D. Mendlein, Strategic Advisor & Director (Age 59)
  • Dr. David J. King, Scientific Consultant (Age 60)
  • Xiang-Lei Yang Ph.D., Founder

When did aTyr Pharma IPO?

(LIFE) raised $76 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

How do I buy shares of aTyr Pharma?

Shares of LIFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is aTyr Pharma's stock price today?

One share of LIFE stock can currently be purchased for approximately $6.16.

How big of a company is aTyr Pharma?

aTyr Pharma has a market capitalization of $23.96 million. The biotechnology company earns $-34,510,000.00 in net income (profit) each year or ($16.11) on an earnings per share basis. aTyr Pharma employs 42 workers across the globe.View Additional Information About aTyr Pharma.

What is aTyr Pharma's official website?

The official website for aTyr Pharma is http://www.atyrpharma.com/.

How can I contact aTyr Pharma?

aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-731-8389 or via email at [email protected]


MarketBeat Community Rating for aTyr Pharma (NASDAQ LIFE)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  361 (Vote Outperform)
Underperform Votes:  424 (Vote Underperform)
Total Votes:  785
MarketBeat's community ratings are surveys of what our community members think about aTyr Pharma and other stocks. Vote "Outperform" if you believe LIFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LIFE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel